No Data
Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.
The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.
Dizal (Jiangsu) Pharmaceutical Presents Trial Results of Lung Cancer Drug in Europe Cancer Journal
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
Dizhe Pharmaceutical "Xilinmen Furniture": Innovative products successfully enter medical insurance and Refinancing has been approved.
Shanghai, December 11, 2024 /PR Newswire/ -- On December 11, 2024, Di Zhe Pharmaceutical announced that its Private Placement plan on the Star has been approved by the Shanghai Stock Exchange. This marks the first approval for refinancing for an unprofitable company since the release of the China Securities Regulatory Commission's "Eight Measures to Deepen the Reform of the Star, Serving Technological Innovation and the Development of New Productive Forces." On November 28, the National Healthcare Security Administration held a press conference to introduce the results of the 2024 adjustments to the national basic Medical, work-related injury insurance, maternity insurance Pharmaceutical catalog for two innovative source products under Di Zhe Pharmaceutical.
Dizhe Pharmaceutical (688192.SH) has obtained approval from the Shanghai Stock Exchange for the issuance of A-shares to specific targets.
Dizhe Pharmaceutical (688192.SH) announced that the company received a notification from the Shanghai Stock Exchange on December 11, 2024...
Dizhe Pharmaceutical (688192.SH): The latest research results on the monotherapy of Shuwozhe for EGFR-TKI resistant non-small cell lung cancer have been published in "Lung Cancer."
Gelonghui, December 11丨Dizhe Pharmaceutical (688192.SH) announced that the latest data from a summary analysis of a phase I/II clinical study of its independently developed new targeted lung cancer drug, Shuwozhe (generic name: Shuwotini tablets), has been published in the official journal of the European Society for Medical Oncology (ESMO) "Lung Cancer". The study shows that Shuwozhe monotherapy has good antitumor activity and safety in patients with non-small cell lung cancer (NSCLC) who are resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).
